2 results match your criteria: "Dr. Werschler is with Spokane Dermatology Clinic and Werschler Aesthetics in Spokane[Affiliation]"
Efficacy and Safety of Microencapsulated Benzoyl Peroxide Cream, 5%, in Papulopustular Rosacea in Elderly Patients: Post-hoc Analysis of Results from Two Randomized, Phase III, Vehicle-controlled Trials.
J Clin Aesthet Dermatol
October 2024
Dr. Werschler is with Spokane Dermatology Clinic and Werschler Aesthetics in Spokane, Washington.
Objective: We sought to compare the efficacy and safety of encapsulated benzoyl peroxide (E-BPO) cream, 5%, versus vehicle in subjects <65 years of age versus subjects ≥65 with moderate to severe papulopustular rosacea.
Methods: This analysis used pooled results from two 12-week, randomized, vehicle-controlled Phase III trials (NCT03564119, NCT03448939) of E-BPO cream, 5%. These trials included 733 subjects randomized 2:1 to E-BPO or vehicle.
Long-term Efficacy and Safety of Microencapsulated Benzoyl Peroxide Cream, 5%, in Rosacea: Results From an Extension of Two Phase III, Vehicle-controlled Trials.
J Clin Aesthet Dermatol
August 2023
Dr. Stein Gold is with Henry Ford Health in Detroit, Michigan.
Objective: We sought to assess the long-term safety and tolerability of microencapsulated benzoyl peroxide cream, 5% (E-BPO cream, 5%), in subjects with rosacea. Efficacy and tolerability have been previously demonstrated in two 12-week, randomized, double-blind, vehicle-controlled Phase III trials.
Methods: In this open-label extension study (NCT03564145; clinicaltrials.